Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab

Cytometry Part B - Clinical Cytometry

Volumn 90, Issue 2, 2016, Pages 168-176

  Wyant, Tim ^a   Estevam, Jose ^a   Yang, Lili ^a   Rosario, Maria ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

crohn's disease; MADCAM 1ACT 1; pharmacodynamics; ulcerative colitis; vedolizumab

Indexed keywords

ALPHA4BETA7 INTEGRIN; DRUG RECEPTOR; EPITOPE; INTEGRIN; MONOCLONAL ANTIBODY; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; UNCLASSIFIED DRUG; VEDOLIZUMAB; BIOLOGICAL MARKER; IMMUNOGLOBULIN; INTEGRIN ALPHA4BETA7; MADCAM1 PROTEIN, HUMAN; MUCOPROTEIN; TRAF3IP2 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

ARTICLE; BLOOD CELL; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DEVELOPMENT; DRUG DETERMINATION; DRUG RESEARCH; FLOW CYTOMETRY; HUMAN; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MEASUREMENT REPEATABILITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR OCCUPANCY PHARMACODYNAMIC ASSAY; REPRODUCIBILITY; ULCERATIVE COLITIS; VALIDATION STUDY; BLOOD; CELL ADHESION; CLINICAL TRIAL; COLITIS, ULCERATIVE; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE; METABOLISM; PATIENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; CELL ADHESION; COLITIS, ULCERATIVE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS; INTEGRINS; LYMPHOCYTES; MUCOPROTEINS; PATIENTS; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS;

EID: 84929773619     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21236     Document Type: Article

References (13)

1. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER,. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330: 864-875.
2. Erle DJ, Briskin MJ, Butcher EC, Garcia-Pardo A, Lazarovits AI, Tidswell M,. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol 1994; 153: 517-528.
3. Briskin MJ, McEvoy LM, Butcher EC,. MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1. Nature 1993; 363: 461-464.
4. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC,. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993; 74: 185-195.
5. Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, Ponich T, Fox I, Feagan BG,. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012; 18: 1470-1479.
6. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, et al., GEMINI 1 Study Group Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
7. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, et al., GEMINI 2 Study Group Vedolizumab as induction and maintenance therapy for crohn's disease. N Engl J Med 2013; 369: 711-721.
8. Lazarovits AI, Moscicki RA, Kurnick JT, Camerini D, Bhan AK, Baird LG, Erikson M, Colvin RB,. Lymphocyte activation antigens. I. A monoclonal antibody, anti-act I, defines a new late lymphocyte activation antigen. J Immunol 1984; 133: 1857-1862.
9. Wyant T, Lackey A, Green M,. Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist. J Transl Med 2008; 6: 76
10. Estevam J, Danaee H, Liu R, Ecsedy J, Trepicchio WL, Wyant T,. Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to aurora a inhibition. J Immunol Methods 2011; 363: 135-142.
11. O'Hara DM, Xu Y, Liang Z, Reddy MP, Wu DY, Litwin V,. Recommendations for the validation of flow cytometric testing during drug development: II assays. J Immunol Methods 2011; 363: 120-134.
12. Purvis N, and, Stelzer G,. Multi-platform, multi-site instrumentation and reagent standardization. Cytometry 1998; 33: 156-165.
13. Biancheri P, Di Sabatino A, Rovedatti L, Giuffrida P, Calarota SA, Vetrano S, Vidali F, Pasini A, Danese S, Corazza GR, et al., Effect of tumor necrosis factor-α blockade on mucosal addressin cell-adhesion molecule-1 in crohn's disease. Inflamm Bowel Dis 2013; 19: 259-264.